Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reproxalap in Dry Eye Disease (Chamber Study)
NCT04971031Phase 2Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dry eye disease (DED) comparing Reproxalap with Vehicle (2 arms). Primary endpoints: Conjunctival Redness Assessed Via Digital Photography at Day 2, Subject-reported Ocular Dryness Score at Day 2 and 1 more. Started Jun 2021; status: completed.
02
Drugs
reproxalap
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04971031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971031.